Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
June 05, 2024
Amidst stagnating levels of development assistance for health, questions about the future of vertical programs such as PEPFAR, lackluster performance on the Sustainable Development Goal for health, and growing calls to address excessive fragmentation in global health, the global health community is ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
Blog Post
October 31, 2022
Many premature deaths from non-communicable diseases can be prevented if countries enact forceful measures to reduce the risk of their citizens falling prey to these diseases. Making it more expensive to consume tobacco, health-harming alcohol, and sugar-sweetened beverages is key to governments ach...
Dec
6
2022
8:30—9:30 AM Eastern Time (US & Canada) / 1:30 - 2:30pm Greenwich Mean Time (GMT)
October 21, 2022
With the post-COVID 19 fiscal crises beginning to impact countries around the world, getting more health for your money has never been so important to policy makers. Countries have turned to priority setting techniques such as Health Technology Assessment (HTA) to ensure priority setting is evidence...
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.